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ABSTRACT
Objective To test the hypothesis that hydroxymethyl
glutaryl coenzyme A reductase inhibitors (statins) may
decrease the risk of community acquired pneumonia.
Design Population based case-control study.
Setting Group Health, a large integrated healthcare
delivery system.
Population Immunocompetent, community dwelling
Group Health members aged 65 to 94; two matched
controls for each case with pneumonia. Information on
comorbid illnesses and functional and cognitive status,
potential confounders of the association between statin
use and risk of pneumonia, came from medical record
review and computerised pharmacy data.
Main outcome measure Adjusted estimates of risk of
pneumonia in relation to current statin use.
Results 1125 validated cases of pneumonia and 2235
matched controls were identified. Compared with
controls, cases were more likely to have chronic lung and
heart disease, especially severe disease, and functional
orcognitiveimpairment.Currentstatinusewaspresentin
16.1% (181/1125) of cases and 14.6% (327/2235) of
controls (adjusted odds ratio 1.26, 95% confidence
interval 1.01 to 1.56). Among cases admitted to hospital
and matched controls, current statin use was present in
17.2% (68/395) of cases and 14.2% (112/788) of
controls (adjusted odds ratio 1.61, 1.08 to 2.39,
compared with non-use). In people in whom statins were
indicated for secondary prevention, the adjusted odds
ratioforriskofpneumoniainrelationtocurrentstatinuse
was 1.25 (0.94 to 1.67); in those with no such indication,
it was 0.81 (0.46 to 1.42).
Conclusions Statin use was not associated with
decreased risk of pneumonia among immunocompetent,
community dwelling older people. Findings of previous
studies may reflect “healthy user” bias.
INTRODUCTION
Hydroxymethyl glutaryl coenzyme A reductase inhi-
bitors, or statins, are widely used to prevent and treat
cardiovascular disease. Interest in their potential to
decrease morbidity and mortality from infection has
grownrecently.Suchabenefitcouldarisefromstatins’
many effects on the inflammatory response and on
immune function,
12 including decreased production
of inflammatory cytokines and interference with neu-
trophil migration and chemotaxis.
3-5 In 2000 Ando et
alpublishedthefirststudyexaminingstatinsandsepsis
in a mouse model, reporting that pretreatment with
cerivastatin improved survival and decreased produc-
tionofcytokinesandnitricoxide.
6In2001Liappisetal
published the first observational study of statins and
infectious outcomes in humans, reporting that among
people admitted to hospital with bacteraemia, mortal-
ity was lower in those receiving statins than in others.
7
Since then, many observational studies have reported
associations between use of statins and decreased risk
of infectious outcomes including pneumonia, bacter-
aemia, sepsis, and mortality from infection,
8-20 and
additional studies have reported decreased mortality
associated with statin treatment in animal models of
sepsis.
21-23
However,reasonsexisttobecautiousininterpreting
results from epidemiological studies of statins and
infectious outcomes. The dramatic negative associa-
tions reported in many of these studies could reflect
bias—for instance, because of underuse of statins in
frail elderly people and in those with more severe
comorbidity,
2425 who are at higher risk of infection.
Observational studies of statins may be subject to
strong “healthy user” effects, as people receiving sta-
tins tend to have less severe comorbidity and better
functional status than others and are more likely to
practise other healthy behaviours.
24-26 Although pre-
vious studies attempted to adjust for comorbidity, this
adjustment has often had substantial limitations, the
most important of which is reliance on administrative
data that may have low sensitivity for the presence of
comorbid illness.
2728 Other important limitations
include adjustment for only a few comorbid condi-
tions; categorising comorbid illnesses very broadly,
which may lead to inadequate adjustment
29; and lack
of data about functional and cognitive status. When
studying the effectiveness of treatment, adjustment
for functional and cognitive status may yield more
valid results than controlling for comorbidity
alone.
2429 In one study of people admitted to hospital
for pneumonia, the initial association between statin
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BMJ | ONLINE FIRST | bmj.com page 1 of 9use and decreased risk of adverse outcomes (mortality
or admission to intensive care unit) became null with
more thorough adjustment, particularly for factors
typically not available in administrative databases
such as measures of functional status and health
behaviours.
25
We had the opportunity to use data from a study of
community acquired pneumonia to examine the
potential benefit of statins in infection. Together with
influenza, pneumonia is the seventh leading cause of
death in people aged 65 and older,
30 and more than
900000 cases of community acquired pneumonia
occur each year among older people in the United
States.
31 Pneumonia provides an excellent model for
studying healthy user bias, because increased risk is
associated with comorbid illness and functional and
cognitive impairment,
31-35 characteristics that are also
associatedwithdecreaseduseofpreventivedrugssuch
as statins.
243637 Two previous observational studies
examined the association between statin use and risk
of pneumonia in large administrative databases and
reported a 30% to 50% lower risk of pneumonia in sta-
tin users compared with non-users.
1011
We analysed data from a case-control study in
immunocompetent,communitydwellingolderpeople
to test the hypothesis that current use of statins is asso-
ciated with decreased risk of community acquired
pneumonia. Our goal was to examine whether statin
use is associated with decreased risk of pneumonia in
older people after control for carefully defined health
and functional status, identified through detailed
review of medical records.
METHODS
Setting
The study took place at Group Health, a large, inte-
gratedhealthcaredeliverysysteminWashingtonState.
Study design and population
These analyses used data from a previous population
based case-control study of risk of pneumonia in rela-
tion to influenza vaccination among immunocompe-
tent, community dwelling older people.
34 The source
population was community dwelling Group Health
members aged 65 to 94 with at least two years of con-
tinuous membership as of 1 September 2000, 2001, or
2002.Weexcludedpeoplewhowereimmunocompro-
mised, defined as having a history of serious cancer,
recenttreatmentforcancer(receivingradiationorche-
motherapy in the previous three months), or chronic
renal failure (creatinine >3 mg/dl, dialysis, or a diag-
nosis of chronic kidney disease); or receiving prescrip-
tions for certain immunosuppressive drugs
(methotrexate, azathioprine, ciclosporin, or muromo-
nab-CD3) or drugs used to treat HIV infection during
thetwoyearsbefore1September.Wedeterminedelig-
ibility for the study from computerised pharmacy,
laboratory, and encounter data and confirmed it by
review of medical records.
Identification of cases and controls
The methods used to identify and validate pneumonia
cases have been described in detail.
38 Briefly, we iden-
tified presumptive cases by using ICD-9 (international
classification of diseases, ninth revision) codes from
inpatient and outpatient encounters (pneumonia
codes: 480 to 487.0 or 507.0) and validated them
through review of chest radiograph reports and hospi-
talrecords.Weexcludedcasesofnosocomialpneumo-
nia or massive aspiration. Because the original study
focused on influenza vaccination and pneumonia
risk, it included pneumonia cases occurring from 1
September until the end of the influenza season in
eachstudyyear(2000-1,2001-2,and2002-3).Forpeo-
ple with multiple episodes of pneumonia, we included
onlythefirstepisode.Figure1showstheflowofpoten-
tial participants through the study.
We selected two controls for each case from the eli-
giblesourcepopulation,matchedonage(±1year),sex,
calendar year,and durationof pneumonia-free follow-
up (incidence density sampling). Pneumonia cases
were not eligible tobe subsequently resampledas con-
trols.
Power calculations indicated that, for a sample size
of1125casesand2235controls,wewouldhaveatleast
85% power to detect odds ratios of 0.67 or more
extreme if the prevalence of statin use was 10% and at
least 95% power if the prevalence was 15% or greater.
Data collection and variable creation
Trainedabstractorsreviewedmedicalrecordstoverify
eligibility and to collect information about comorbid
illnesses, lifestyle and demographic factors, healthcare
utilisation, and functional and cognitive status. Medi-
cal records were reviewed in the same way for cases
and controls. The medical record review focused on
the two year period before 1 September of each year
Group Health members aged 65-94 years (n=53 929)
Eligible on basis of administrative data (n=46 824; 87%)
Exclude recurrent cases
and their matched controls
Presumptive first episodes of
community acquired
pneumonia (n=4006)
Validated cases of
community acquired
pneumonia (n=1173)
Validated (n=1481; 37%)
Ineligible after chart review
(living in an institution or
immunocompromised) (n=308; 21%)
Matched controls (n=2346)
Cases (n=1125) Controls (n=2235)
Fig 1 | Selection of cases and controls for inclusion in study
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detailedassessmentofthepresenceandseverityofvar-
ioushealthconditions,focusingonthosehypothesised
to be associated with risk of pneumonia. Measures of
functional status included documentation in the chart
of need for assistance with ambulation or bathing, use
ofhomehealthservices,andwhetherapersonwasever
described as frail by medical personnel. The measure
of cognitive status was the presence of a physician’s
diagnosisofdementiainthechart.Informationonpre-
vious cholesterol concentrations came from compu-
terised laboratory data.
Information about drug use came from a compu-
terised pharmacy database. In previous studies, 98%
of Group Health members in this age group have
reported filling all or almost all of their prescriptions
at Group Health pharmacies.
39 We obtained data
about prescriptions for a wide variety of drugs used to
treatchronicheartandlungdisease,astheseconditions
are associated with increased risk of pneumonia and
we hypothesised that use of these drugs might be an
indicator for severity of heart or lung disease. We
also obtained information about other drugs hypothe-
sisedtoinfluenceriskofpneumonia,suchasH2 recep-
tor blockers and proton pump inhibitors.
Definition of current statin use
To determine whether people were current users of
statins at the time of diagnosis of pneumonia, we
defined an “index date” for each case as the date of
diagnosis of pneumonia, which was defined as the
date of the first positive chest radiograph or, for cases
admitted to hospital with no radiology report avail-
able, the date of admission. Controls were assigned
the sameindexdate astheirmatched case.Wedefined
current statin use as receipt of least two prescriptions
for a statin within the 180 days before the index date.
Statistical analyses
To examine characteristics associated with pneumo-
nia,wecalculatedproportionsforcategoricalvariables
and medians and interquartile ranges for continuous
variables according to pneumonia status. We did simi-
lar analyses to identify characteristics associated with
currentstatin useamongcontrolparticipants.Wethen
usedconditionallogisticregressiontoestimatethe risk
of pneumonia associated with current statin use, with
robuststandarderrorstoaccountforpossiblerepeated
sampling of controls. Partially adjusted models
included only the matching variables (age, sex, and
calendar year), and fully adjusted multivariable mod-
els also included comorbid illnesses, lifestyle and
demographiccharacteristics,andfunctionalandcogni-
tive status. We selected covariates for inclusion in the
finalmodelsasfollows.Wegeneratedalistofpotential
confoundingfactors on the basis of clinical plausibility
and review of the literature. We examined these in
descriptive analyses and selected for our final models
those that seemed to be substantially associated with
either risk of pneumonia or use of statin (no set P
value was needed, as we thought that this was overly
arbitrary). Certain characteristics were not included in
the final models because their prevalence in the popu-
lationwasextremelylow.Foranalysesinwhichadmis-
sion to hospital for community acquired pneumonia
was the outcome, we selected confounders for inclu-
sioniftheywereassociatedwithstatinuseoradmission
to hospital for pneumonia. Missing values were a
Table 1 |Characteristics of pneumonia cases and controls. Values are numbers (percentages)
unless stated otherwise
Characteristic* Pneumonia cases (n=1125) Controls (n=2235)
Median (interquartile range) age
(years)†
77 (72-83) 77 (71-82)
Male† 571 (50.8) 1135 (50.8)
Asthma 195 (17.3) 176 (7.9)
Chronic obstructive pulmonary disease 350 (31.1) 234 (10.5)
Admitted to hospital for chronic
obstructive pulmonary disease‡
53 (4.7) 15 (0.7)
Congestive heart failure 207 (18.4) 156 (7.0)
Ejection fraction measured‡ 78 (6.9) 40 (1.8)
History of myocardial infarction 137 (12.2) 217 (9.7)
History of coronary revascularisation 155 (13.8) 250 (11.2)
Other heart disease 447 (39.7) 708 (31.7)
Hypertension 514 (45.7) 1048 (46.9)
Total cholesterol >6.2 mmol/l 339 (30.1) 715 (32.0)
Cholesterol not measured 287 (25.5) 542 (24.3)
Home oxygen use 92 (8.2) 21 (0.9)
Longtermuseofcorticosteroidsforlung
disease
29 (2.6) 8 (0.4)
Median(interquartilerange)Noofvisits
in previous year
11 (6-17) 8 (5-14)
Median (interquartilerange)body mass
index (kg/m
2)
25.9 (22.8-30.3) (n=799) 27.1 (24.4-30.3) (n=1481)
Smoking status:
Current smoker 103/1109 (9.3) 115/2182 (5.3)
Recently quit 25/1109 (2.3) 33/2182 (1.5)
History of stroke 93 (8.3) 153 (6.8)
Swallowing dysfunction 17 (1.5) 11 (0.5)
Alcoholism 17 (1.5) 24 (1.1)
Diabetes mellitus 194 (17.2) 337 (15.1)
With complications 107 (9.5) 182 (8.1)
Dementia 53 (4.7) 75 (3.4)
Need assistance with bathing 24 (2.1) 15 (0.7)
Need assistance with walking 198 (17.6) 250 (11.2)
Use of home health services‡ 161 (14.3) 137 (6.1)
Ever described as “frail”‡ 88 (7.8) 64 (2.9)
Bronchodilator use§ 147 (13.1) 60 (2.7)
Inhaled corticosteroid use§ 258 (22.9) 175 (7.8)
Oral corticosteroid use§ 174 (15.5) 111 (5.0)
Furosemide use§ 254 (22.6) 228 (10.2)
Insulin or oral hypoglycaemic use§ 129 (11.5) 209 (9.4)
Acid suppressing drug use§ 247 (22.0) 358 (16.0)
Influenza vaccination¶ 681 (60.5) 1374 (61.5)
Pneumococcal vaccination** 1031 (91.6) 2046 (91.5)
*Defined as of 1 September unless otherwise noted.
†Matching variable used in selection of controls.
‡During two year baseline period.
§Defined as filling at least one prescription for drug in this class during two year baseline period; acid
suppressing drugs defined as H2 receptor blockers and proton pump inhibitors.
¶Receipt of current year’s influenza vaccine before index date.
**Defined as any history of receiving pneumococcal vaccine.
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models—smokingstatusandcholesterol—andwetrea-
ted them as a separate category, using indicator vari-
ables. We used SAS version 9.1 for analyses.
Sensitivity analyses
To assess whether our definition of statin use affected
the results, we did two additional analyses. Firstly, we
repeated the primary analysis with a stricter definition
of non-use, in which we excluded “possible” statin
users from the non-use (referent) group but included
them in the model as a separate category. We defined
“possibleusers”asthosewhohadatleastoneprescrip-
tionforastatinintheyearbeforetheindexdatebutdid
not meet the definition of current statin use. Secondly,
we repeated the primary analysis with current statin
users redefined as people whose most recent prescrip-
tion for a statin would be expected to last at least until
the index date, on the basis of the days’ supply dis-
pensed and assuming 80% compliance. To assess the
impactofcovariateselectiononourresults,wecreated
a parsimonious model that adjusted only for matching
factors and those covariates which, when included in
models, altered the statin-pneumonia odds ratio by
10% or more. In addition, we repeated our primary
analyses in subgroups defined by the presence of indi-
cationsforstatinuse.The“secondaryprevention”sub-
group included people with congestive heart failure,
stroke, diabetes, history of myocardial infarction or
coronary revascularisation, or other heart disease,
and the “primary prevention” subgroup included peo-
ple lacking these conditions. Because of the matched
study design, only cases and controls concordant for
primary versus secondary prevention could be
included in these analyses.
Finally, we attempted to examine the impact of sev-
eralaspectsofourstudydesign,includingvalidationof
pneumonia cases and restriction of the cohort, in
analyses using only administrative and pharmacy
data. Within the entire source cohort, we identified
presumptive pneumonia cases from ICD-9 codes and
did Cox proportional hazards regression modelling to
estimatetheassociationbetweencurrentstatinuseand
riskof pneumonia.Wedidcrudeanalyses withoutany
restrictionoradjustment.Wethendidanalysesinclud-
ing both restriction and adjustment. Using administra-
tive and pharmacy data, we excluded people with
chronic renal disease, cancer or cancer treatment,
moderateor severeliver disease,hospicecare,nursing
home residence, or use of immunosuppressive drugs.
We adjusted for covariates including age, sex, number
of outpatient visits, drug use (for example, bronchodi-
lators,furosemide,inhaledororalcorticosteroids),and
comorbid illnesses.
40 We attempted to mirror the pri-
mary analyses used in the case-control studyas closely
as possible given the limitations of the administrative
and pharmacy data.
RESULTS
Study population
We found 53929 people aged 65 to 94 who were
Group Health members as of 1 September in one of
the study years, including 46824 (87%) who met elig-
ibility criteria on the basis of electronic data sources
and thus made up the source cohorts. Within this
group, 4006 first episodes of presumptive community
acquired pneumonia occurred during follow-up, of
which 1481 (37%) were validated. Of these, 308
(21%)wereineligibleonthebasisofchartreview,leav-
ing 1173 cases, for whom we selected 2346 matched
controls. For these analyses, we did not allow partici-
pants to be included as a case in more than one year,
thus excluding another 48 cases and their matched
controls. Thus, the population for these analyses con-
sisted of 1125 validated pneumonia cases and 2235
matched controls. Of the 1125 cases, 395 (35.1%)
Model Cases
Primary analysis (minimally adjusted)
Primary analysis (fully adjusted)
Primary analysis (most parsimonious  model)*
Primary analysis (fully adjusted) – excluded "possible" statin users†
No indication for statin use for secondary prevention (fully adjusted)†
Indication for statin use for secondary prevention (fully adjusted)†
Cases admitted to hospital only (fully adjusted)
Alternative definition for "current" statin use (fully adjusted)§
Cohort analysis (minimally adjusted) – no restriction of cohort
Cohort analysis (fully adjusted) – restricted cohort¶ 
1.13 (0.95 to 1.34)
1.26 (1.01 to 1.56)
1.12 (0.93 to 1.36)
1.19 (0.96 to 1.48)
0.81 (0.46 to 1.42)
1.25 (0.94 to 1.67)
1.61 (1.08 to 2.39)
1.15 (0.94 to 1.42)
1.12 (1.03 to 1.21)
0.99 (0.90 to 1.09)
2235
2235
2235
2235
504
649
788
2235
NA
NA
1125
1125
1125
1125
360
492
395
1125
5021
3712
0.5 1.0 1.5 2.0 2.5
Odds ratio (95% CI) Odds ratio (95% CI) Controls
Fig 2 | Risk estimates for association between statin use and community acquired pneumonia: sensitivity analyses. Current
statin use defined as at least two prescriptions for statin within 180 days before index date; pneumonia outcomes defined
from ICD-9 codes for cohort analyses and validated by medical record review for all other analyses. NA=not applicable.
*Adjusted for matching variables, history of chronic obstructive pulmonary disease (with or without hospital admission), and
other heart disease. †Possible statin use defined as receipt of at least one prescription for statin in previous year but not
meeting criteria for current use; possible users removed from non-user (referent) group but included in model as separate
category. ‡Indication for statin for secondary prevention defined as presence of at least one of congestive heart failure, stroke,
diabetes, history of myocardial infarction or coronary revascularisation, or other heart disease. §On basis of days’ supply of
most recent filled prescription. ¶All restrictions and adjustments based on administrative and pharmacy data
RESEARCH
page 4 of 9 BMJ | ONLINE FIRST | bmj.comwere admitted to hospital, and the remainder were
treated as outpatients; 62 (5.5%) cases died within
30 days of their index date.
Characteristics of pneumonia cases and controls
Comparedwithcontrols,peoplewithpneumoniawere
morelikelytohave chroniclungandheartdiseaseand
tohavemoreseverelungandheartdiseaseasindicated
by several measures of severity (table 1). For instance,
cases were more likely than controls to be receiving
home oxygen, chronic oral corticosteroids, or furose-
mideand,amongthosewithcongestiveheartfailure,to
have had their ejection fractionmeasured.In addition,
cases were more likely to be current smokers and to
have evidence of functional or cognitive impairment,
suchasneedingassistancewithbathingorambulation.
Characteristics associated with current statin use
Amongourstudyparticipants,636hadreceivedatotal
of 6176 prescriptions for a statin in the 12 months
before the index date. The most commonly used drug
wassimvastatin,whichaccountedfor76%(4699/6176)
of prescriptions, followed by lovastatin (19%; 1194/
6176) and atorvastatin (3.5%; 216/6176). Pravastatin
and fluvastatin were rarely used.
Among controls, statin use was more common
among men than among women (table 2). It was
strongly associated with heart disease and with cardio-
vascular risk factors, including diabetes mellitus and
treated hypertension. Statin users showed healthier
behaviour than non-users in several regards: they
were less likely to be current smokers and more likely
to have received influenza or pneumococcal vaccine.
Inaddition,overallhealthstatuswasbetteramongcur-
rentstatinusers,whowerelesslikelytoneedassistance
with bathing or ambulation than non-users and less
likely to have been described as “frail” in the chart.
Association between current statin use and pneumonia risk
We found no association between current statin use
and decreased risk of pneumonia in models with mini-
mal or full adjustment (table 3). The fully adjusted
odds ratio for pneumonia in statin users, compared
with non-users, was 1.26 (95% confidence interval
1.01to1.56)(table 4).Inmodelslimitedtopneumonia
cases admitted to hospital and their matched controls,
statinuserswereathigherriskthannon-users.Current
statinusewasseenin17.2%(68/395)ofadmittedcases
and14.2%(112/788)oftheirmatchedcontrols,andthe
adjusted odds ratio was 1.61 (1.08 to 2.39) (table 5).
Sensitivity analyses
We got similar results from a parsimonious model
adjusting only for matching factors and those covari-
ates that altered the statin-pneumonia odds ratio by
10% or more (chronic obstructive pulmonary disease,
hospital admission for chronic obstructive pulmonary
disease, and other heart disease): the adjusted odds
ratioforcurrentstatinusewas1.12(0.93to1.36)(fig2).
Analysesthatexcluded“possible”statinusers(those
withatleastoneprescriptionforastatinintheprevious
year but not meeting criteria for current use) from the
non-usergroupalsoyieldedsimilarresults:forallcom-
munity acquired pneumonia the adjusted odds ratio
comparing current statin users with non-users 1.22
(0.98to1.51),andforcommunityacquiredpneumonia
requiring hospital admission it was 1.61 (1.08 to 2.41).
Table 2 |Characteristics associated with statin use among controls. Values are numbers
(percentages) unless stated otherwise
Characteristic* No current statin use (n=1908)
Current statin use†
(n=327)
Median (interquartile range) age (years) 77 (71-82) 76 (71-80)
Male 920 (48.2) 215 (65.7)
Asthma 141 (7.4) 35 (10.7)
Chronic obstructive pulmonary disease 206 (10.8) 28 (8.6)
Admitted to hospital for chronic
obstructive pulmonary disease‡
12 (0.6) 3 (0.9)
Congestive heart failure 130 (6.8) 26 (8.0)
Ejection fraction measured‡ 29 (1.5) 11 (3.4)
History of myocardial infarction 121 (6.3) 96 (29.4)
History of coronary revascularisation 130 (6.8) 120 (36.7)
Other heart disease 496 (26.0) 212 (64.8)
Hypertension 845 (44.3) 203 (62.1)
Total cholesterol >6.2 mmol/l 551 (28.9) 164 (50.2)
Cholesterol not measured 542 (28.4) 0 (0)
Home oxygen use 19 (1.0) 2 (0.6)
Long term use of corticosteroids for lung
disease
7( 0 . 4 ) 1( 0 . 3 )
Median (interquartile range) No of visits in
previous year
9 (5-15) 11 (6-17)
Median (interquartile range) body mass
index (kg/m
2)
26.8 (23.8-30.4) (n=1242) 28.2(25.5-31.2)(n=239)
Smoking status:
Current smoker 100/1863 (5.4) 15/319 (4.7)
Recently quit 30/1863 (1.6) 3/319 (0.9)
History of stroke 120 (6.3) 33 (10.1)
Swallowing dysfunction 8 (0.4) 3 (0.9)
Alcoholism 23 (1.2) 1 (0.3)
Diabetes mellitus 253 (13.3) 84 (25.7)
With complications 134 (7.0) 48 (14.7)
Dementia 64 (3.4) 11 (3.4)
Need assistance with bathing 15 (0.8) 0 (0.0)
Need assistance with walking 226 (11.8) 24 (7.3)
Use of home health services‡ 118 (6.2) 19 (5.8)
Ever described as “frail”‡ 60 (3.1) 4 (1.2)
Bronchodilator use§ 50 (2.6) 10 (3.1)
Inhaled corticosteroid use§ 150 (7.9) 25 (7.6)
Oral corticosteroid use§ 94 (4.9) 17 (5.2)
Furosemide use§ 191 (10.0) 37 (11.3)
Insulin or oral hypoglycaemic use§ 148 (7.8) 61 (18.7)
Acid suppressing drug use§ 282 (14.8) 76 (23.2)
Influenza vaccination¶ 1159 (60.7) 215 (65.7)
Pneumococcal vaccination** 1737 (91.0) 309 (94.5)
*Defined as of 1 September unless otherwise noted.
†Defined as receiving two or more prescriptions for statin in six months before index date.
‡During two year baseline period.
§Defined as filling at least one prescription for drug in this class during two year baseline period; acid
suppressing medications defined as H2 receptor blockers and proton pump inhibitors.
¶Receipt of current year’s influenza vaccine before index date.
**Defined as any history of receiving pneumococcal vaccine.
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the basis of the days’ supply of the last prescription
before the index date, results were again similar: for
all community acquired pneumonia the adjusted
odds ratio for current statin use was 1.15 (0.94 to
1.42) compared with non-use, and for community
acquired pneumonia requiring hospital admission it
was 1.44 (0.98 to 2.13).
Werepeatedourprimaryanalysesinsubgroupsstra-
tified by indication for statin use (grouped broadly as
primary versus secondary prevention). Because of the
matched study design, about 25% (273/1125) of cases
and 50% (1082/2235) of controls had to be excluded
because they were discordant for this characteristic. In
the primary prevention subgroup, current statin use
was seen in 4.4% (16/360) of pneumonia cases and
5.4% (27/504) of controls, and the adjusted odds ratio
was 0.81 (0.46 to 1.42). In the secondary prevention
subgroup, statins were used by 25.2% (124/492) of
casesand25.7%(167/649)ofcontrols,andtheadjusted
odds ratio was 1.25 (0.94 to 1.67).
Othersensitivityanalysesincluded theentiresource
cohort and defined pneumonia on the basis of ICD-9
codes (without validation). The crude analyses
included 5021 events, of which 720 (14%) occurred in
statinusers,andyieldedacrudeoddsratioof1.12(1.03
to 1.21) for the association between current statin use
andriskofpneumonia.Furtheranalysesthatrestricted
the source cohort and adjusted for covariates on the
basis of administrative and pharmacy data included
3712 events, 537 (14%) of which occurred in statin
users, and the corresponding risk estimate was 0.99
(0.90 to 1.09.).
DISCUSSION
In this population based case-control study of immuno-
competent,communitydwellingolderpeople,wefound
no decreased risk of pneumonia associated with current
use of statins. For all cases of community acquired
pneumonia, if anything a slight increase in risk was
associated with current statin use (adjusted odds ratio
1.26, 95% confidence interval 1.01 to 1.56, compared
with non-use). For pneumonia leading to admission to
hospital, the increased risk was greater still (adjusted
odds ratio 1.61, 1.08 to 2.39).
Study strengths and limitations
Strengthsofourstudyincludeextensiveeffortstomini-
mise confounding, including both “healthy user” bias
and confounding by indication, and the validation of
allpneumoniaoutcomes.Firstly,weusedrestrictionto
focus on relatively healthy, community dwelling
Table 3 |Current statin use and risk of community acquired pneumonia. Values are numbers (percentages) unless stated
otherwise
Pneumonia cases
(n=1125) Controls (n=2235)
Odds ratio (95% CI)
Minimally adjusted* Fully adjusted†
No current statin use 944 (83.9) 1908 (85.4) Reference Reference
Current statin use 181 (16.1) 327 (14.6) 1.13 (0.95 to 1.34) 1.26 (1.01 to 1.56)
*Adjusted for matching variables of age, sex, and calendar year.
†Further adjusted for asthma, chronic obstructive pulmonary disease, history of hospital admission for chronic obstructive pulmonary disease, use of
home oxygen, smoking status (current, recent quitter, former smoker, or missing), congestive heart failure, measurement of ejection fraction, history
of stroke, swallowing disorder, alcoholism, diabetes, presence of complications of diabetes, history of myocardial infarction, coronary
revascularisation, other heart disease, hypertension, high cholesterol, need for assistance with ambulation or bathing, dementia, frailty, and use of
the following drugs: inhaled bronchodilators, inhaled corticosteroids, oral corticosteroids, or furosemide.
Table 4 |Results of multivariable regression model for statin use and risk of community
acquired pneumonia*
Characteristic Adjusted odds ratio (95% CI)
Current statin use† 1.26 (1.01 to 1.56)
Asthma 1.20 (0.93 to 1.55)
Chronic obstructive pulmonary disease, no hospital admission 1.80 (1.47 to 2.21)
Chronic obstructive pulmonary disease, with previous hospital
admission
1.95 (0.96 to 3.94)
Home oxygen use 2.44 (1.6 to 4.10)
Current smoker 1.67 (1.26 to 2.21)
Recently quit smoking 1.25 (0.73 to 2.13)
Former smoker 1.24 (1.06 to 1.44)
Smoking status missing 0.78 (0.47 to 1.28)
Congestive heart failure, ejection fraction not measured 1.67 (1.25 to 2.23)
Congestive heart failure, with ejection fraction measurement 3.08 (1.98 to 4.77)
Bronchodilator use† 1.65 (1.19 to 2.30)
Furosemide use† 1.26 (0.99 to 1.59)
Inhaled corticosteroid use† 1.37 (1.04 to 1.81)
Oral corticosteroid use† 1.60 (1.24 to 2.06)
History of stroke 1.00 (0.77 to 1.29)
Swallowing disorder 2.39 (1.22 to 4.70)
Alcoholism 1.46 (0.83 to 2.56)
Diabetes, no complications 0.98 (0.75 to 1.28)
Diabetes, with complications 1.13 (0.88 to 1.45)
History of myocardial infarction 0.90 (0.72 to 1.14)
History of coronary revascularisation 0.91 (0.71 to 1.17)
Other heart disease 1.16 (0.97 to 1.38)
Hypertension 0.83 (0.72 to 0.95)
No cholesterol value >6.2 mmol/l 1.04 (0.87 to 1.25)
At least one cholesterol value >6.2 mmol/l 0.96 (0.79 to 1.16)
Need assistance bathing 1.90 (1.07 to 3.35)
Uses walking aid: cane 1.21 (0.92 to 1.59)
Uses walking aid: walker 1.46 (1.02 to 2.08)
Uses wheelchair or bedridden 1.46 (0.94 to 2.26)
Ever described as frail 1.77 (1.26 to 2.48)
Dementia 1.34 (0.94 to 1.90)
*Conditional logistic regression used to account for matching; pneumonia cases and controls matched for age,
sex, and calendar year. Referent categories are as follows: for smoking variables, never smoker; for diabetes
variables, no diabetes; for walking variables, no need for assistance with ambulation; for cholesterol values, no
cholesterol measurement available.
†Current statin use defined as receiving two or more prescriptions in six month period before index date; other
drug use variables defined as receiving at least one prescription for drug in that class in two year baseline
period.
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may exist compared with an unselected older popula-
tion including residents in nursing homes and people
with serious or terminal illness. More specifically, we
excluded immunocompromised people, who may be
at higher risk of pneumonia but less likely to receive
statin treatment. Our use of medical record review as
well as pharmacy data to determine eligibility criteria,
comorbid illness, and functional and cognitive status
probably resulted in more accurate ascertainment of
confounding factors, including measures of severity
of comorbid illnesses. We reviewed and validated all
casesofpneumonia,specificallyexcludingnosocomial
pneumonia, which may reduce confounding from
health differences between statin users and non-users.
Ourstudyalsohassomelimitations.Informationon
exposure came from computerised pharmacy data, so
misclassification of exposure is possible if participants
filled prescriptions outside of Group Health or filled a
prescription but failed to take the drug. However, we
note that in previous studies, 98% of Group Health
members in this age group have reported filling all or
almostallprescriptionsatGroupHealthpharmacies.
39
Consistent with the demographics of Washington
State, Group Health members are predominantly
white, so our findings may not be generalisable to
other racial and ethnic groups. Because of our focus
on community acquired pneumonia in a relatively
healthy population, we cannot answer the question of
whetherstatinsmaybebeneficialinasicker,morefrail
elderly population, such as nursing home residents or
immunosuppressed people.
Comparison with previous studies
Our results differ from the findings of two previous
studies that examined use of statins and risk of pneu-
monia. In a case-control study limited to people with
diabetes, van den Garde et al found a reduced risk in
current statin users (adjusted odds ratio 0.49, 0.35 to
0.69, compared with non-users).
10 Schlienger et al did
a case-control study within the general practice
research database and found an association of statin
use with decreased risk of pneumonia (adjusted odds
ratio0.71,0.56to0.89).
11Theassociationwasstrongest
for fatal pneumonia (adjusted odds ratio 0.47, 0.25 to
0.88) and was not significant for pneumonia treated in
the outpatient setting (adjusted odds ratio 0.84, 0.61 to
1.17). Several methodological differences exist
between these studies and ours that may explain the
divergent results. Whereas we extensively reviewed
medical records, both the previous studies relied on
large electronic databases, which may have limited
sensitivityforimportantcomorbidconditions.Neither
previous study excluded nursing home residents, a
group that may be particularly frail and susceptible to
pneumonia yet have reduced likelihood of receiving a
statin. Neither previous study identified nor adjusted
for measures of functional or cognitive status. All of
these aspects may have contributed to healthy user
bias in these studies. Notably, Majumdar et al studied
patientsadmittedtohospitalforpneumoniaandfound
that analyses adjusting only for typical administrative
variables found a decreased risk of mortality or admis-
sion to an intensive care unit among statin users com-
pared with non-users, whereas analyses with more
thorough adjustment, including for functional status,
showednoassociation,andtheirfinalriskestimatesug-
gested increased risk among current statin users.
25
These findings are consistent with ours and support
the idea that healthy user bias may help to explain
why our results differ from those of van de Garde and
Schlienger.
1011
Possible biological mechanisms
A biological basis could exist for the increased risks
thatweandMajumdaretalfoundamongcurrentstatin
users.
25 By altering the immune response, statins may
impairhostdefencemechanisms,leadingtothespread
of infection. One study in which mice were inoculated
with Klebsiella pneumoniae found increased bacterial
growth and enhanced systemic dissemination of bac-
teriainstatintreatedmice.
4Alternatively,thisapparent
increasedriskcouldbeduetochanceoritcouldreflect
residual confounding by indication, particularly in the
hospital admission outcome, as statin use is associated
Table 5 |Results of multivariable regression model for statin use and risk of admission to
hospital for community acquired pneumonia*
Characteristic Adjusted odds ratio (95% CI)
Current statin use† 1.61 (1.08 to 2.39)
Ever received pneumococcal vaccine 0.66 (0.42 to 1.04)
Asthma 1.36 (0.88 to 2.10)
Chronic obstructive pulmonary disease 1.94 (1.38 to 2.72)
Chronic obstructive pulmonary disease, with measurement of
forced expiratory volume in 1 second
2.21 (1.30 to 3.75)
Current smoker or recent quitter 3.26 (2.03 to 5.24)
Former smoker 1.46 (1.08 to 1.96)
Smoking status missing 1.02 (0.45 to 2.29)
Congestive heart failure, ejection fraction not measured 1.61 (1.01 to 2.57)
Congestive heart failure, with ejection fraction measurement 1.48 (0.70 to 3.13)
Furosemide use† 1.64 (1.08 to 2.49)
Insulin use† 2.31 (1.26 to 4.22)
Oral corticosteroid use† 2.59 (1.71 to 3.92)
Diabetes, no complications 1.18 (0.67 to 2.08)
Diabetes, with complications 0.79 (0.43 to 1.44)
History of myocardial infarction 1.19 (0.80 to 1.78)
History of coronary revascularisation 0.64 (0.42 to 0.99)
Other heart disease 1.21 (0.87 to 1.68)
Hypertension 0.99 (0.76 to 1.28)
History of stroke 1.15 (0.80 to 1.66)
Need assistance with bathing 1.92 (0.78 to 4.71)
Uses walking aid: cane 1.77 (1.13 to 2.76)
Uses walking aid: walker 2.42 (1.40 to 4.20)
Uses wheelchair or bedridden 4.18 (2.06 to 8.48)
Dementia 1.64 (0.91 to 2.96)
*Conditional logistic regression used to account for matching; pneumonia cases and controls matched for age,
sex, and calendar year. Referent categories are as follows: smoking variables, never smoker; for walking
variables, no need for assistance with ambulation.
†Current statin use defined as receiving two or more prescriptions in six month period before index date; other
drug use variables defined as receiving at least one prescription for drug in that class in two year baseline
period.
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failure that may influence the decision to admit
patients with pneumonia.
Conclusions and policy implications
Our results suggest that caution is warranted in attri-
buting benefits to statin use that may instead reflect
unmeasured differences between users and non-users.
Althoughwe examined risk of developing community
acquiredpneumonia,ratherthanoutcomesafterpneu-
monia or sepsis, our findings may be relevant to that
area of research as well, suggesting that great care
should be taken in interpreting the findings of studies
of sepsis and infectious mortality, in which similar pat-
terns of confounding may exist. That is, as is true for
pneumonia, some groups at particularly high risk for
sepsis and infectious mortality—such as nursing home
residents, people with serious cancer or chronic renal
disease, or immunosuppressed people—may be less
likely to receive statin treatment, an example of the
healthy user effect.
Onthebasisofpreviousobservationalstudies,some
investigators have called for randomised trials of sta-
tins for prevention or treatment of sepsis and lung dis-
easeandhavesuggestedthatstatinscouldbebeneficial
incasesofpandemicinfluenza.
910141541-44Accordingto
Clinicaltrials.gov, five randomised clinical trials of sta-
tinsin the settingof sepsisare currentlyunderway,
45-49
with numbers of participants ranging from 20 to 250,
and an additional randomised trial is examining venti-
lator associated pneumonia.
50 We believe that invest-
ing additional resources in trials may be premature,
given the weaknesses of the observational research in
thisareaandresultinguncertaintiesaboutthetrueben-
efitsofstatinuse.Instead,anindividuallevelmeta-ana-
lysis of existing data from randomised placebo
controlled trials of statins might be useful to examine
infectious outcomes such as pneumonia or sepsis.
Our findings highlight some of the limitations of
large administrative databases in studying some unan-
ticipated effects of commonly used drugs such as the
statins. These results are particularly relevant, as the
use of administrative data sources for research pur-
poses continues to increase and widen in scope. For
example, the Sentinel Initiative, which was launched
by the US Food and Drug Administration in May
2008, aims to monitor safety of medical products by
combiningexistingdatasourcessuchasadministrative
medical claims data to support research on a popula-
tion of 100 million people by 2012.
51 Our work sug-
gests that policy makers as well as researchers should
carefully consider the limitations of such data, particu-
larly regarding the ability to characterise the popula-
tion exposed and not exposed to certain drugs. More
work needs to be done to learn how to improve the
content of large administrative databases by incorpor-
ating richer and more detailed data, including clinical
data, which should become increasingly feasible with
the growing use of electronic medical records. Such
detailed data may be critical to obtaining valid results
in studies of some drug-disease associations.
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